Who owns IOVANCE BIOTHERAPEUTICS, INC.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of IOVA from SEC Form 13F filings across 334 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 334 institutions disclosed 277.5M shares of IOVANCE BIOTHERAPEUTICS, INC. worth $4.11B — about 60.9% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
334
13F holders
$4.11B
value, 2026 filers
60.9%
of shares outstanding (277.5M sh)
78
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of IOVA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 37.9M | $561.7M | 0.0% | 8.3% | +2.6% |
| 2 | MHR FUND MANAGEMENT LLC | 29.0M | $429.3M | 21.1% | 6.4% | 0.0% |
| 3 | STATE STREET CORP | 21.7M | $321.5M | 0.0% | 4.8% | -11.4% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 18.4M | $272.6M | 0.0% | 4% | +1.1% |
| 5 | TWO SIGMA INVESTMENTS, LP | 15.0M | $221.8M | 0.2% | 3.3% | -21.3% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 12.3M | $182.0M | 0.0% | 2.7% | -14.7% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 10.5M | $154.9M | 0.0% | 2.3% | +1.2% |
| 8 | D. E. Shaw & Co., Inc. | 9.2M | $135.8M | 0.1% | 2% | +327.6% |
| 9 | DIMENSIONAL FUND ADVISORS LP | 6.2M | $92.4M | 0.0% | 1.4% | -3.4% |
| 10 | GOLDMAN SACHS GROUP INC | 4.9M | $73.2M | 0.0% | 1.1% | -3.1% |
| 11 | Nuveen, LLC | 4.7M | $68.9M | 0.0% | 1% | -6.9% |
| 12 | MORGAN STANLEY | 4.5M | $66.5M | 0.0% | 1% | -10.1% |
| 13 | JANE STREET GROUP, LLC | 4.2M | $61.9M | 0.0% | 0.9% | -5.0% |
| 14 | NORTHERN TRUST CORP | 4.1M | $60.7M | 0.0% | 0.9% | -1.4% |
| 15 | BANK OF AMERICA CORP /DE/ | 4.0M | $59.8M | 0.0% | 0.9% | -19.2% |
| 16 | AQR CAPITAL MANAGEMENT LLC | 3.7M | $55.5M | 0.0% | 0.8% | -3.3% |
| 17 | JUPITER ASSET MANAGEMENT LTD | 3.7M | $54.5M | 0.3% | 0.8% | -18.9% |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.6M | $53.4M | 0.0% | 0.8% | +11.9% |
| 19 | Palo Alto Investors LP | 3.5M | $51.4M | 7.7% | 0.8% | -34.5% |
| 20 | MPM BIOIMPACT LLCNEW | 2.8M | $42.0M | 3.1% | 0.6% | new |
| 21 | WELLS FARGO & COMPANY/MN | 2.8M | $41.2M | 0.0% | 0.6% | -14.3% |
| 22 | VANGUARD FIDUCIARY TRUST CO | 2.7M | $39.3M | 0.0% | 0.6% | +4.2% |
| 23 | UBS Group AG | 2.6M | $37.8M | 0.0% | 0.6% | +97.5% |
| 24 | JPMORGAN CHASE & CO | 2.5M | $36.6M | 0.0% | 0.6% | +4.2% |
| 25 | Rhenman & Partners Asset Management AB | 2.5M | $37.1M | 4.1% | 0.5% | +46.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.